Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Production / Operations

Profound Surpasses 2025 TULSA-PRO(TM) Installed Base Goal

By The Northwire Desk — AI Analysis Jan 12, 2026 · 08:00 PRN · 11.71 PROFOUND MEDICAL CORP.
PRN · Price

Executive Summary

  • Profound Medical reported an installed base of 78 TULSA‑PRO® systems as of Dec 31, 2025, surpassing its target of 75 installations.
  • The qualified sales pipeline grew to 97 new systems in the “Verify, Negotiate and Contracting” stages at year‑end.
  • Management indicated that a larger installed base is expected to drive higher patient treatment rates and increase recurring high‑margin revenue; full Q4 2025 and FY 2025 results are slated for release in February 2026.

Key Details

  • Installed Base: 78 TULSA‑PRO® systems worldwide as of Dec 31, 2025 (goal was 75).
  • Sales Pipeline: 97 qualified new TULSA‑PRO® systems classified within “Verify, Negotiate and Contracting” stages at year‑end.
  • Revenue Outlook: Management expects the expanding installed base to boost patient treatment volumes and recurring revenue streams.
  • Upcoming Disclosure: Fourth‑quarter and full‑year 2025 financial results will be released near the end of February 2026.
  • Product Portfolio Reminder: Profound also markets Sonalleve®, a CE‑marked platform for uterine fibroids, adenomyosis, bone metastasis pain palliation, desmoid tumors, and osteoid osteoma; it holds approvals in Canada, the U.S., China, and Europe.

Notable Quotes

  • “As the installed base grows, we expect that it will lead to higher patient treatment rates and, correspondingly, continued growth of our high margin recurring revenue,” – Arun Menawat, CEO & Chairman, Profound Medical Corp.
Read the original news release →

More from PROFOUND MEDICAL CORP.

May 15, 2026 · 06:30

Profound Medical Corp.

Other May 14, 2026 · 07:00

TULSA-PRO's Conference Glow Hides a Long Road to Profitability

Other May 07, 2026 · 16:05

Humana coverage and surging procedure volumes push TULSA-PRO toward standard of care, but path to profitability still requires execution.

Earnings Mar 27, 2026 · 15:15

Profound talks up Tulsa procedure milestone in Texas

Production / Operations Mar 27, 2026 · 07:45

Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

Other Mar 13, 2026 · 10:30

CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure(TM) to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence

Other